1. Home
  2. Clinical Topics
  3. FDA warns of drug interactions between Victrelis and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors
Clinical TopicsDrugs and DevicesImmune/Lymphatic SystemWeb Exclusives

FDA warns of drug interactions between Victrelis and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors

Share

On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts